Dark Forest Capital Management LP Purchases 78,078 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Dark Forest Capital Management LP boosted its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 82.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 172,623 shares of the biotechnology company's stock after acquiring an additional 78,078 shares during the period. Arrowhead Pharmaceuticals accounts for about 0.5% of Dark Forest Capital Management LP's holdings, making the stock its 22nd biggest position. Dark Forest Capital Management LP owned 0.14% of Arrowhead Pharmaceuticals worth $3,245,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. World Investment Advisors LLC increased its holdings in shares of Arrowhead Pharmaceuticals by 3.8% in the third quarter. World Investment Advisors LLC now owns 19,132 shares of the biotechnology company's stock worth $371,000 after purchasing an additional 700 shares during the period. Franklin Resources Inc. raised its holdings in shares of Arrowhead Pharmaceuticals by 9.4% in the 3rd quarter. Franklin Resources Inc. now owns 19,251 shares of the biotechnology company's stock valued at $373,000 after acquiring an additional 1,658 shares in the last quarter. Nordea Investment Management AB boosted its position in shares of Arrowhead Pharmaceuticals by 6.3% during the 4th quarter. Nordea Investment Management AB now owns 132,188 shares of the biotechnology company's stock valued at $2,463,000 after acquiring an additional 7,776 shares during the last quarter. First Citizens Bank & Trust Co. purchased a new position in shares of Arrowhead Pharmaceuticals during the fourth quarter worth about $205,000. Finally, KBC Group NV increased its position in shares of Arrowhead Pharmaceuticals by 45.9% in the fourth quarter. KBC Group NV now owns 5,224 shares of the biotechnology company's stock worth $98,000 after purchasing an additional 1,644 shares during the last quarter. Institutional investors own 62.61% of the company's stock.

Arrowhead Pharmaceuticals Trading Up 2.3 %

Shares of ARWR opened at $12.36 on Wednesday. The stock has a market capitalization of $1.70 billion, a P/E ratio of -2.39 and a beta of 0.99. Arrowhead Pharmaceuticals, Inc. has a twelve month low of $9.57 and a twelve month high of $30.41. The company has a quick ratio of 6.09, a current ratio of 6.09 and a debt-to-equity ratio of 7.27. The firm has a fifty day simple moving average of $14.99 and a two-hundred day simple moving average of $18.50.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last posted its earnings results on Monday, February 10th. The biotechnology company reported ($1.39) earnings per share for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.97). On average, research analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Christopher Richard Anzalone sold 133,333 shares of Arrowhead Pharmaceuticals stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $17.02, for a total transaction of $2,269,327.66. Following the sale, the chief executive officer now owns 3,773,802 shares of the company's stock, valued at approximately $64,230,110.04. The trade was a 3.41 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last 90 days, insiders sold 276,839 shares of company stock worth $4,054,176. 4.30% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

ARWR has been the subject of a number of research reports. Chardan Capital reissued a "buy" rating and issued a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, February 11th. Royal Bank of Canada reissued an "outperform" rating and issued a $42.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, February 11th. B. Riley reiterated a "buy" rating and issued a $38.00 price objective (down from $51.00) on shares of Arrowhead Pharmaceuticals in a report on Friday, February 14th. Finally, HC Wainwright reissued a "buy" rating and set a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Wednesday, February 12th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $41.44.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.